Phase II GEM-CESAR: Post Hoc Analyses of Sustained uMRD at 4 Yr After KRd + ASCT for High-Risk MM

Potentially curative therapy with KRd followed by ASCT, KRd consolidation, and lenalidomide maintenance in high-risk smoldering MM is encouraging, with 43% of patients MRD negative at 4 years and only 6% progressing to active MM.